Establishment and validation of a 28-day mortality prediction model based on the lactate dehydrogenase/albumin ratio in patients with severe pneumonia

LAR is an effective biomarker with significant clinical value in predicting 28-day mortality in patients with severe pneumonia. The LAR-based prediction model enhances the accuracy of mortality risk assessment, especially in non-septic patients. Combined with machine learning techniques, LAR offers a novel tool for early clinical risk evaluation and holds promising potential for clinical application.